Michael Giordano MD

Michael Giordano, M.D., is Senior Vice President, Head of Oncology Development at Bristol-Myers Squibb (BMS). Michael is accountable to the Chief Scientific Officer. He has responsibility for developing innovative Oncology medicines that meaningfully improve the standard of care for patients. Michael ensures the creation of high performing Oncology development teams who deliver all components of asset development past proof of concept. As Chair of the Oncology Development Committee, Michael plays a key governance role for all global development decisions for our Oncology assets. In addition, he or his team is responsible for Oncology Global Clinical Research and the Pharmacodiagnostics function. He is also a core member of the R&D Pipeline Strategy Committee which is the forum for major portfolio decisions, asset/ indication strategy, and investment tradeoff decisions on new opportunities.

Prior to his current position, Michael has held various roles at Bristol-Myers Squibb including SVP, Head of Oncology and Immunoscience Development, VP of global development teams across all late stage assets, and Head of Virology and Oncology for Medical Affairs in Europe.

Prior to joining BMS, Michael was Assistant Professor of Medicine and Infectious Diseases at Cornell University Medical College and head of their clinical trials organization in HIV medicine. Michael received his M.D. from Cornell University Medical College in New York and received post doctoral training at New York Hospital, Memorial Sloan Kettering, and Weill-Cornell Medical College.